Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 10th June 2020
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

European Commission approves Elanco's acquisition of Bayer Animal Health
"We look forward to turning our full attention to delivering innovation"  - Jeff Simmons, Elanco.

Approval "an important milestone" toward completion.

The proposed acquisition of Bayer's animal health division by Elanco has been approved by the European Commission (EC).

In a press release, Elanco said that it continues to progress toward a mid-year closing, anticipated August 3, 2020. The deal, valued at $7.6 billion, would see Elanco become the second largest company in the animal health sector.

“Approval from the European Commission is an important milestone toward the completion of our acquisition of Bayer Animal Health," commented Jeff Simmons, president and CEO of Elanco.

“As the transaction edges closer to fruition, we look forward to turning our full attention to delivering innovation and an expanded portfolio of solutions for farmers, veterinarians and pet owners across the globe."

Elanco previously announced divestiture agreements, in the range of $120 million to $140 million, to help advance the needed regulatory reviews. The EC’s approval is conditional on several of these proposed divestitures, including:

  • divestiture of the worldwide rights for Osurnia® to Dechra Pharmaceuticals
  • divestiture of the worldwide rights for Vecoxan® to Merck Animal Health
  • divestiture of European Economic Area and UK rights to the Drontal® and Profender® product families, and related pipeline assets, from Bayer Animal Health to Vetoquinol.
     
Mr Simmons continued: “The recent months have only underscored the critical work our farmers do in delivering meat, milk, fish and eggs, and the importance of providing pet owners and veterinarians with a variety of solutions in multiple channels from telemedicine and e-commerce to direct home delivery. Combining Bayer Animal Health’s leadership in these areas better positions Elanco to deliver on these needs.”

 

Become a member or log in to add this story to your CPD history

Strangles survey seeks views of horse owners

News Story 1
 With Strangles Awareness Week just around the corner (5-11 May), vets are being encouraged to share a survey about the disease with their horse-owning clients.

The survey, which has been designed by Dechra, aims to raise awareness of Strangles and promote best practices to prevent its transmission. It includes questions about horse owners' experiences of strangles, together with preventative measures and vaccination.

Respondents to the survey will be entered into a prize draw to win two VIP tickets to Your Horse Live 2025. To access the survey, click here 

Click here for more...
News Shorts
Vivienne Mackinnon elected BVA Scottish Branch President

The British Veterinary Association (BVA) has elected Vivienne Mackinnon as its new BVA Scottish Branch president.

Dr Mackinnon has over 30 years of experience in veterinary care, encompassing both small animal and mixed practice. She has worked in practices in Scotland, England, New Zealand and Australia, before joining APHA to work in frontline disease control.

In her speech, Dr Mackinnon reflected on the changes in Scotland's veterinary industry and highlighted her commitment to veterinary education.

Dr Mackinnon said: "I look forward to working with colleagues across the veterinary professions to improve animal health and welfare in the country and support veterinary workplaces."